November 13, 2021
1 min watch
Save
VIDEO: iDose shows sustained IOP reduction at 2 years
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
NEW ORLEANS — In this Healio Video Perspective from the AAO meeting, John P. Berdahl, MD, discusses 2-year data from the iDose (sustained-release travoprost implant, Glaukos) phase 2 trial.